Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2A receptors

Synapse

Volumn 60, Issue 3, 2006, Pages 239-250

  Morissette, Marc ^a   Dridi, Mehdi ^a   Calon, Frédéric ^a   Tahar, Abdallah Hadj ^a,b   Meltzer, Leonard T ^c   Bédard, Paul J ^a,b   Di Paolo, Thérèse ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c PFIZER INC   (United States)

Author keywords

Adenosine receptor; Dyskinesia; Glutamate receptor; Levodopa; MPTP

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CI 1041; DOPAMINE; IODINE 125; LEVODOPA; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; DENERVATION; DYSKINESIA; FEMALE; IN SITU HYBRIDIZATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIPARKINSON AGENTS; BENZOXAZOLES; DENERVATION; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; LEVODOPA; MACACA FASCICULARIS; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OLIGONUCLEOTIDE PROBES; OVARIECTOMY; PARKINSON DISEASE, SECONDARY; PIPERIDINES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, N-METHYL-D-ASPARTATE; TRIAZOLES;

EID: 33745810560     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20295     Document Type: Article

References (80)

1. Albin RL, Makowiec RL, Hollingsworth ZR, Dure LS IV, Penney JB, Young AB. 1992. Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study. Neuroscience 46:35-48.
2. Alexander SP, Reddington M. 1989. The cellular localization of adenosine receptors in rat neostriatum. Neuroscience 28:645-651.
3. Bai G, Kusiak JW. 1993. Cloning and analysis of the 5′ flanking sequence of the rat N-methyl-D-aspartate receptor 1 (NMDAR1) gene. Biochim Biophys Acta 1152:197-200.
4. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN. 2003. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61:293-296.
5. Beckstead RM, Cruz CJ. 1986. Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience 19:147-158.
6. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184:285-294.
7. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. 1996. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 23:189-193.
8. Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. 1997. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev 21:447-453.
9. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. 1999. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J Pharmacol Exp Ther 290:1034-1040.
10. Blandini F. 2003. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: Potential targets for a new therapeutic approach. Exp Neurol 184:556-560.
11. 2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 46:251-257.
12. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. 2002. Increase of preproenkephalin mRNA levels in the putamen of Parkinson's disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61:186-196.
13. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. 2003. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14:404-416.
14. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127 (Part 5):1075-1084.
15. Chase TN, Oh JD. 2000. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47(4, Suppl 1):S122-S129; discussion S129, S130.
16. Chu YY, Tu KH, Lee YC, Kuo ZJ, Lai HL, Chern Y. 1996. Characterization of the rat A2a adenosine receptor gene. DNA Cell Biol 15:329-337.
17. Cole RL, Konradi C, Douglass J, Hyman SE. 1995. Neuronal adaptation to amphetamine and dopamine: Molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 14:813-823.
18. 2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur J Pharmacol 464:33-38.
19. Dingledine R, Borges K, Bowie D, Traynelis SF. 1999. The glutamate receptor ion channels. Pharmacol Rev 51:7-61.
20. 3H]-SCH 58261. Br J Pharmacol 121:353-360.
21. 2A receptors elicits zif/268 and NMDA ε2 subunit mRNA expression in cortex and striatum of the "weaver" mutant mouse, a genetic model of nigrostriatal dopamine deficiency. Neuroscience 123:1025-1036.
22. Engber TM, Papa SM, Boldry RC, Chase TN. 1994. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport 5:2586-2588.
23. Ferre S, O'Connor WT, Fuxe K, Ungerstedt U. 1993. The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain. J Neurosci 13:5402-5406.
24. 2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14:186-195.
25. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
26. 2 receptor. Brain Res Mol Brain Res 15:62-66.
27. Goulet M, Morissette M, Grondin R, Falardeau P, Bedard PJ, Rostene W, Di Paolo T. 1999. Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Synapse 32:153-164.
28. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-1677.
29. 2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion. J Neural Transm 107:851-859.
30. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321-327.
31. Kincaid AE, Wilson CJ. 1996. Corticostriatal innervation of the patch and matrix in the rat neostriatum. J Comp Neurol 374:578-592.
32. Klein M, Pieri I, Uhlmann F, Pfizenmaier K, Eisel U. 1998. Cloning and characterization of promoter and 5′-UTR of the NMDA receptor subunit ε2: Evidence for alternative splicing of 5′-non-coding exon. Gene 208:259-269.
33. Klockgether T, Turski L. 1993. Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia. Ann Neurol 34:585-593.
34. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. 2000. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54:1589-1595.
35. Kosinski CM, Standaert DG, Counihan TJ, Scherzer CR, Kerner JA, Daggett LP, Velicelebi G, Penney JB, Young AB, Landwehrmeyer GB. 1998. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus. J Comp Neurol 390:63-74.
36. Kotter R. 1994. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 44:163-196.
37. Latini S, Pedata F. 2001. Adenosine in the central nervous system: Release mechanisms and extracellular concentrations. J Neurochem 79:463-484.
38. 2A adenosine receptor gene function as negative translational regulators. J Neurochem 73:1790-1798.
39. Lundblad M, Vaudano E, Cenci MA. 2003. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem 84:1398-1410.
40. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. 1996. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 736:202-205.
41. Marin C, Jimenez A, Bonastre M, Chase TN, Tolosa E. 2000. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse 36:267-274.
42. 2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 42:697-706.
43. 2A receptor mRNA expression is increased in rat striatum and nucleus accumbens after memantine administration. Mol Brain Res 120:193-196.
44. Metman LV, Del Dotto P, Natte R, van den Munckhof P, Chase TN. 1998. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51:203-206.
45. Metman LV, Konitsiotis S, Chase TN. 2000. Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what. Mov Disord 15:3-8.
46. Montastruc JL, Rascol O, Senard JM. 1997. Glutamate antagonists and Parkinson's disease: A review of clinical data. Neurosci Biobehav Rev 21:477-480.
47. 2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 251:21-25.
48. 2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy. Brain Res Mol Brain Res 49:55-62.
49. 2 receptor agonists. J Neurochem 72:682-692.
50. Morissette M, Dridi M, Calon F, Tahar AH, Meltzer L, Bedard PJ, Di Paolo T. 2006. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B NMDA receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin. Mov Disord 21:9-17.
51. Nash JE, Brotchie JM. 2000. A common signaling pathway for striatal NMDA and adenosine A2a receptors: Implications for the treatment of Parkinson's disease. J Neurosci 20:7782-7789.
52. Nikam SS, Meltzer LT. 2002. NR2B selective NMDA receptor antagonists. Curr Pharm Des 8:845-855.
53. 2A adenosine receptors. J Pharmacol Sci 94:100-102.
54. Obeso JA, Olanow CW, Nutt JG. 2000a. Levodopa motor complications in Parkinson's disease. Trends Neurosci 23(10, Suppl):S2-S7.
55. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. 2000b. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model. Ann Neurol 47(4, Suppl 1):S22-S32; discussion S32-S34.
56. 2A receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience 127:223-231.
57. Papa SM, Chase TN. 1996. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574-578.
58. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. 1995. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701:13-18.
59. Parent A, Hazrati LN. 1995. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 20:91-127.
60. Peterfreund RA, MacCollin M, Gusella J, Fink JS. 1996. Characterization and expression of the human A2a adenosine receptor gene. J Neurochem 66:362-368.
61. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39:233-238.
62. Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, Morelli M. 2002. Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 446:75-82.
63. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, Hornykiewicz O. 2002. Clinical-pathological study of levodopa complications. Mov Disord 17:289-296.
64. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. 2000. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study group. N Engl J Med 342:1484-1491.
65. 2 receptor mRNA in the human brain. Neurosci Lett 130:177-181.
66. Snow BJ, Macdonald L, McAuley D, Wallis W. 2000. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin Neuropharmacol 23:82-85.
67. Svenningsson P, Hall H, Sedvall G, Fredholm BB. 1997. Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. Synapse 27:322-335.
68. 2A receptor mRNA in the primate striatum. J Comp Neurol 399:229-240.
69. 2A receptors. Prog Neurobiol 59:355-396.
70. Szabo J, Cowan WM. 1984. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J Comp Neurol 222:265-300.
71. Tahar AH, Gregoire L, Bangassoro E, Bedard PJ. 2000. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 23:195-202.
72. 2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. Eur J Pharmacol 412:247-254.
73. Tahar AH, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ. 2004. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 15:171-176.
74. Tel BC, Zeng BY, Cannizzaro C, Pearce RK, Rose S, Jenner P. 2002. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115:1047-1058.
75. 2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. Synapse 52:218-222.
76. Weisinger G. 1995. The transcriptional regulation of the preproenkephalin gene. Biochem J 307 (Part 3):617-629.
77. Widmann R, Sperk G. 1986. Topographical distribution of amines and major amine metabolites in the rat striatum. Brain Res 367:244-249.
78. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310.
79. Yaar R, Jones MR, Chen JT, Ravid K. 2005. Animal models for the study of adenosine receptor function. J Cell Physiol 202:9-20.
80. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. 2000. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12:1096-1104.